![Virtual Booth](https://www.pharmacompass.com/image/vb/vb-orange-btn.png)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-desktop-w27gif-57924.gif)
![Minakem Generic APIs](https://www.pharmacompass.com/image/flap/minakem-header-mobile-w27gif-62411.gif)
Active Filter(s):
Details:
Under the agreement, GENFIT will advance Celloram’s first-in-class inflammasome inhibitor, CLM-022, a triterpenoid derivative that targets the inflammasome machinery, in liver disease indications.
Lead Product(s): CLM-022
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: CLM-022
Highest Development Status: Preclinical Product Type: Small molecule
Partner/Sponsor/Collaborator: Genfit
Deal Size: $175.5 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 31, 2023